Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Renal Insufficiency, Chronic | 59 | 2024 | 2296 | 4.130 |
Why?
|
Kidney Failure, Chronic | 33 | 2023 | 2491 | 3.110 |
Why?
|
Renal Dialysis | 18 | 2023 | 1802 | 2.540 |
Why?
|
Diabetic Nephropathies | 16 | 2024 | 975 | 2.450 |
Why?
|
Kidney Transplantation | 19 | 2023 | 4300 | 2.150 |
Why?
|
Calcinosis | 9 | 2013 | 1481 | 1.640 |
Why?
|
Glomerular Filtration Rate | 34 | 2024 | 2226 | 1.640 |
Why?
|
Coronary Artery Disease | 12 | 2022 | 6567 | 1.110 |
Why?
|
Erectile Dysfunction | 4 | 2021 | 445 | 1.030 |
Why?
|
Nephrology | 4 | 2023 | 270 | 0.900 |
Why?
|
Kidney Diseases | 11 | 2023 | 2103 | 0.770 |
Why?
|
Disease Progression | 22 | 2023 | 13646 | 0.650 |
Why?
|
Kidney | 17 | 2024 | 7064 | 0.630 |
Why?
|
Renal Replacement Therapy | 2 | 2021 | 283 | 0.620 |
Why?
|
Albuminuria | 10 | 2023 | 658 | 0.590 |
Why?
|
Cardiovascular Diseases | 22 | 2024 | 15649 | 0.590 |
Why?
|
Diabetes Mellitus, Type 2 | 14 | 2024 | 12241 | 0.580 |
Why?
|
Interleukin-6 | 5 | 2022 | 3230 | 0.560 |
Why?
|
Diabetes Mellitus | 8 | 2022 | 5891 | 0.540 |
Why?
|
Diabetic Retinopathy | 2 | 2023 | 1299 | 0.540 |
Why?
|
Lipoprotein(a) | 3 | 2007 | 490 | 0.480 |
Why?
|
Arteriovenous Shunt, Surgical | 3 | 2017 | 291 | 0.460 |
Why?
|
Fibroblast Growth Factors | 4 | 2016 | 873 | 0.440 |
Why?
|
Coronary Vessels | 4 | 2014 | 3125 | 0.400 |
Why?
|
C-Reactive Protein | 4 | 2021 | 3857 | 0.390 |
Why?
|
Health Literacy | 3 | 2014 | 468 | 0.390 |
Why?
|
Heart Valves | 1 | 2013 | 284 | 0.380 |
Why?
|
Catheters, Indwelling | 2 | 2012 | 436 | 0.370 |
Why?
|
Diabetes Mellitus, Type 1 | 6 | 2023 | 3440 | 0.360 |
Why?
|
Polytetrafluoroethylene | 1 | 2012 | 245 | 0.360 |
Why?
|
Humans | 133 | 2024 | 768393 | 0.360 |
Why?
|
Middle Aged | 70 | 2024 | 223491 | 0.330 |
Why?
|
Graft Survival | 5 | 2023 | 3900 | 0.330 |
Why?
|
Hypertriglyceridemia | 2 | 2003 | 293 | 0.310 |
Why?
|
Allopurinol | 2 | 2020 | 198 | 0.300 |
Why?
|
Male | 80 | 2024 | 364902 | 0.300 |
Why?
|
United States Government Agencies | 1 | 2008 | 26 | 0.300 |
Why?
|
Adult | 60 | 2024 | 223640 | 0.300 |
Why?
|
Cohort Studies | 31 | 2022 | 41795 | 0.300 |
Why?
|
Kidney Function Tests | 8 | 2024 | 681 | 0.300 |
Why?
|
Prospective Studies | 32 | 2022 | 54920 | 0.290 |
Why?
|
Tunica Intima | 1 | 2009 | 459 | 0.280 |
Why?
|
Renal Insufficiency | 3 | 2023 | 809 | 0.280 |
Why?
|
Minority Health | 1 | 2008 | 79 | 0.280 |
Why?
|
Blood Pressure | 5 | 2021 | 8541 | 0.280 |
Why?
|
Aged | 54 | 2024 | 171562 | 0.260 |
Why?
|
Female | 75 | 2024 | 397089 | 0.260 |
Why?
|
Cholesterol, HDL | 3 | 2014 | 1820 | 0.260 |
Why?
|
Glaucoma | 1 | 2015 | 1194 | 0.250 |
Why?
|
Uric Acid | 3 | 2022 | 806 | 0.250 |
Why?
|
Heart Valve Diseases | 1 | 2013 | 1030 | 0.250 |
Why?
|
Aorta | 2 | 2011 | 2046 | 0.250 |
Why?
|
Acute Kidney Injury | 3 | 2024 | 1943 | 0.240 |
Why?
|
Carotid Stenosis | 1 | 2012 | 862 | 0.240 |
Why?
|
Carotid Arteries | 1 | 2009 | 943 | 0.240 |
Why?
|
Renin-Angiotensin System | 5 | 2020 | 739 | 0.240 |
Why?
|
Cystatin C | 3 | 2023 | 272 | 0.240 |
Why?
|
Health Priorities | 1 | 2008 | 380 | 0.240 |
Why?
|
Atherosclerosis | 4 | 2024 | 3431 | 0.230 |
Why?
|
Coronary Disease | 3 | 2014 | 5924 | 0.230 |
Why?
|
Heart Failure | 10 | 2024 | 11858 | 0.220 |
Why?
|
Proteinuria | 3 | 2019 | 613 | 0.220 |
Why?
|
Hyperglycemia | 2 | 2022 | 1389 | 0.220 |
Why?
|
Risk Factors | 32 | 2024 | 74962 | 0.220 |
Why?
|
Creatinine | 7 | 2024 | 1915 | 0.220 |
Why?
|
Proteomics | 4 | 2024 | 3906 | 0.210 |
Why?
|
United States | 26 | 2024 | 73150 | 0.210 |
Why?
|
Efficiency, Organizational | 1 | 2008 | 700 | 0.210 |
Why?
|
Lipocalins | 2 | 2014 | 161 | 0.210 |
Why?
|
Sleep Apnea Syndromes | 1 | 2011 | 982 | 0.210 |
Why?
|
Aortic Diseases | 1 | 2009 | 741 | 0.210 |
Why?
|
Myocardial Infarction | 7 | 2021 | 11516 | 0.210 |
Why?
|
Acute-Phase Proteins | 2 | 2014 | 251 | 0.200 |
Why?
|
Osteopontin | 1 | 2024 | 307 | 0.200 |
Why?
|
Health Policy | 2 | 2021 | 2698 | 0.200 |
Why?
|
Diet, Sodium-Restricted | 1 | 2024 | 291 | 0.200 |
Why?
|
Resistin | 1 | 2022 | 172 | 0.190 |
Why?
|
Organ Transplantation | 2 | 2003 | 1177 | 0.190 |
Why?
|
Prevalence | 9 | 2020 | 15872 | 0.190 |
Why?
|
Coronary Stenosis | 1 | 2007 | 802 | 0.180 |
Why?
|
Peripheral Arterial Disease | 3 | 2021 | 1303 | 0.180 |
Why?
|
Inflammation | 4 | 2016 | 10863 | 0.180 |
Why?
|
Xanthine Oxidase | 1 | 2020 | 69 | 0.170 |
Why?
|
Adipokines | 1 | 2022 | 309 | 0.170 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2001 | 213 | 0.170 |
Why?
|
Aspartate Aminotransferases | 1 | 2021 | 414 | 0.170 |
Why?
|
Cultural Diversity | 1 | 2023 | 373 | 0.170 |
Why?
|
Insulin Resistance | 1 | 2013 | 3981 | 0.160 |
Why?
|
Policy | 1 | 2023 | 514 | 0.160 |
Why?
|
Kidney Tubules | 2 | 2024 | 448 | 0.160 |
Why?
|
Alleles | 2 | 2023 | 6892 | 0.160 |
Why?
|
Glomerulonephritis, Membranoproliferative | 1 | 1999 | 41 | 0.160 |
Why?
|
Regression Analysis | 4 | 2013 | 6350 | 0.160 |
Why?
|
Troponin T | 2 | 2014 | 787 | 0.160 |
Why?
|
Hypoglycemic Agents | 5 | 2024 | 3108 | 0.160 |
Why?
|
Sodium | 3 | 2022 | 1594 | 0.160 |
Why?
|
Alanine Transaminase | 1 | 2021 | 605 | 0.160 |
Why?
|
Spin Labels | 1 | 2020 | 339 | 0.150 |
Why?
|
Cryoglobulinemia | 1 | 1999 | 84 | 0.150 |
Why?
|
Hyperlipidemias | 1 | 2003 | 773 | 0.150 |
Why?
|
Metformin | 2 | 2024 | 911 | 0.150 |
Why?
|
Cardiomyopathies | 2 | 2024 | 2056 | 0.150 |
Why?
|
Financing, Government | 1 | 2021 | 473 | 0.140 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2010 | 1891 | 0.140 |
Why?
|
Serine Endopeptidases | 1 | 2022 | 1026 | 0.140 |
Why?
|
Research Personnel | 1 | 2021 | 590 | 0.140 |
Why?
|
Research Support as Topic | 1 | 2021 | 696 | 0.140 |
Why?
|
Risk Adjustment | 1 | 2020 | 603 | 0.140 |
Why?
|
Thyroid Diseases | 1 | 2000 | 387 | 0.130 |
Why?
|
Adiponectin | 1 | 2022 | 1117 | 0.130 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12558 | 0.130 |
Why?
|
Obesity, Abdominal | 2 | 2016 | 375 | 0.130 |
Why?
|
Incidence | 8 | 2024 | 21544 | 0.130 |
Why?
|
Hematoma | 1 | 2020 | 768 | 0.130 |
Why?
|
Hypertrophy, Left Ventricular | 4 | 2015 | 856 | 0.120 |
Why?
|
Body Mass Index | 5 | 2016 | 13052 | 0.120 |
Why?
|
Obesity | 4 | 2021 | 13084 | 0.120 |
Why?
|
Single-Cell Analysis | 2 | 2024 | 2533 | 0.120 |
Why?
|
Health Status Disparities | 3 | 2021 | 1882 | 0.120 |
Why?
|
Cause of Death | 4 | 2021 | 3728 | 0.120 |
Why?
|
Uromodulin | 1 | 2014 | 48 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2010 | 4047 | 0.120 |
Why?
|
Exercise | 1 | 2011 | 5946 | 0.120 |
Why?
|
Hypertension | 3 | 2024 | 8615 | 0.120 |
Why?
|
Cross-Sectional Studies | 10 | 2020 | 26375 | 0.120 |
Why?
|
N-Acetylgalactosaminyltransferases | 1 | 2014 | 63 | 0.120 |
Why?
|
Tissue Donors | 2 | 2023 | 2389 | 0.120 |
Why?
|
Hepacivirus | 1 | 2021 | 1342 | 0.120 |
Why?
|
Patient Education as Topic | 1 | 2024 | 2337 | 0.110 |
Why?
|
Bicarbonates | 1 | 2015 | 292 | 0.110 |
Why?
|
Leptin | 1 | 2022 | 1597 | 0.110 |
Why?
|
Drug Therapy, Combination | 1 | 2024 | 6318 | 0.110 |
Why?
|
Natriuretic Peptide, Brain | 3 | 2024 | 1751 | 0.110 |
Why?
|
Adiposity | 2 | 2014 | 1895 | 0.110 |
Why?
|
Hepatitis C, Chronic | 1 | 2021 | 1031 | 0.110 |
Why?
|
Fibrinogen | 2 | 2014 | 891 | 0.110 |
Why?
|
Patient Preference | 1 | 2020 | 947 | 0.110 |
Why?
|
Markov Chains | 2 | 2017 | 977 | 0.100 |
Why?
|
Catheterization, Central Venous | 1 | 2017 | 536 | 0.100 |
Why?
|
Lymphoma, B-Cell | 1 | 1999 | 945 | 0.100 |
Why?
|
Chromatin | 1 | 2024 | 2968 | 0.100 |
Why?
|
Hospitalization | 5 | 2020 | 10844 | 0.100 |
Why?
|
Young Adult | 15 | 2020 | 60049 | 0.100 |
Why?
|
Health Care Costs | 2 | 2017 | 3267 | 0.090 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4526 | 0.090 |
Why?
|
Apolipoproteins | 1 | 2013 | 328 | 0.090 |
Why?
|
Potassium | 1 | 2015 | 1318 | 0.090 |
Why?
|
Risk Assessment | 9 | 2024 | 24318 | 0.090 |
Why?
|
Intra-Abdominal Fat | 1 | 2016 | 624 | 0.090 |
Why?
|
Osteoprotegerin | 1 | 2011 | 179 | 0.090 |
Why?
|
Multivariate Analysis | 6 | 2016 | 12092 | 0.090 |
Why?
|
Quality of Health Care | 2 | 2018 | 4339 | 0.090 |
Why?
|
Waist-Hip Ratio | 1 | 2012 | 520 | 0.090 |
Why?
|
Immunosuppressive Agents | 3 | 2010 | 4209 | 0.090 |
Why?
|
Pulsatile Flow | 1 | 2011 | 320 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 6 | 2017 | 16028 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 7 | 2017 | 20765 | 0.090 |
Why?
|
Piperazines | 1 | 2001 | 2552 | 0.090 |
Why?
|
Cadherins | 1 | 2014 | 906 | 0.080 |
Why?
|
Peptide Fragments | 3 | 2024 | 5151 | 0.080 |
Why?
|
Inflammation Mediators | 2 | 2016 | 1890 | 0.080 |
Why?
|
Polycystic Kidney Diseases | 1 | 2010 | 133 | 0.080 |
Why?
|
Postoperative Complications | 3 | 2008 | 15881 | 0.080 |
Why?
|
Enzyme Inhibitors | 1 | 2020 | 3722 | 0.080 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2010 | 234 | 0.080 |
Why?
|
Intraocular Pressure | 1 | 2015 | 1304 | 0.080 |
Why?
|
Pulse | 1 | 2009 | 218 | 0.080 |
Why?
|
Quality-Adjusted Life Years | 2 | 2017 | 1735 | 0.080 |
Why?
|
Survival Analysis | 3 | 2018 | 10117 | 0.080 |
Why?
|
Cataract | 1 | 2015 | 837 | 0.080 |
Why?
|
Acculturation | 1 | 2010 | 179 | 0.080 |
Why?
|
Lipoproteins, HDL | 1 | 2013 | 682 | 0.080 |
Why?
|
Smoking | 3 | 2016 | 9111 | 0.080 |
Why?
|
Histocompatibility Testing | 2 | 2008 | 716 | 0.080 |
Why?
|
Membrane Proteins | 2 | 2022 | 7880 | 0.080 |
Why?
|
Chromosome Mapping | 1 | 2017 | 4622 | 0.080 |
Why?
|
Consensus | 3 | 2022 | 3212 | 0.080 |
Why?
|
Graft Occlusion, Vascular | 1 | 2012 | 538 | 0.080 |
Why?
|
Health Expenditures | 1 | 2021 | 2395 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3413 | 0.070 |
Why?
|
Ankle Brachial Index | 2 | 2021 | 163 | 0.070 |
Why?
|
Genetic Loci | 1 | 2017 | 2630 | 0.070 |
Why?
|
Sympathetic Nervous System | 1 | 2010 | 521 | 0.070 |
Why?
|
Time Factors | 8 | 2018 | 40272 | 0.070 |
Why?
|
DNA Methylation | 1 | 2021 | 4421 | 0.070 |
Why?
|
Comorbidity | 4 | 2017 | 10588 | 0.070 |
Why?
|
Gene Expression Profiling | 1 | 2023 | 9510 | 0.070 |
Why?
|
Stroke | 3 | 2021 | 9742 | 0.070 |
Why?
|
Hypolipidemic Agents | 2 | 2003 | 609 | 0.070 |
Why?
|
Morbidity | 1 | 2012 | 1758 | 0.070 |
Why?
|
Fatty Liver | 1 | 2013 | 807 | 0.070 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2017 | 1459 | 0.070 |
Why?
|
Lipids | 2 | 2008 | 3344 | 0.070 |
Why?
|
Statistics as Topic | 1 | 2013 | 2363 | 0.070 |
Why?
|
Tacrolimus | 1 | 2010 | 750 | 0.070 |
Why?
|
Quality of Life | 3 | 2021 | 13503 | 0.070 |
Why?
|
Postmenopause | 1 | 2016 | 2518 | 0.070 |
Why?
|
Follow-Up Studies | 6 | 2014 | 39407 | 0.070 |
Why?
|
Vasodilation | 1 | 2010 | 968 | 0.070 |
Why?
|
Drug Utilization | 1 | 2012 | 1191 | 0.070 |
Why?
|
Health Promotion | 1 | 2018 | 2209 | 0.070 |
Why?
|
Odds Ratio | 4 | 2021 | 9682 | 0.070 |
Why?
|
HLA-A Antigens | 1 | 2007 | 223 | 0.070 |
Why?
|
Community-Institutional Relations | 1 | 2008 | 208 | 0.070 |
Why?
|
Women's Health | 1 | 2016 | 2078 | 0.070 |
Why?
|
Hemodynamics | 2 | 2020 | 4199 | 0.060 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1795 | 0.060 |
Why?
|
Biomedical Research | 1 | 2021 | 3464 | 0.060 |
Why?
|
Insulin | 1 | 2020 | 6607 | 0.060 |
Why?
|
HLA-B Antigens | 1 | 2007 | 328 | 0.060 |
Why?
|
Treatment Failure | 2 | 2020 | 2663 | 0.060 |
Why?
|
Pain | 1 | 2020 | 5103 | 0.060 |
Why?
|
Triglycerides | 2 | 2014 | 2465 | 0.060 |
Why?
|
Prognosis | 6 | 2016 | 30022 | 0.060 |
Why?
|
HLA-DR Antigens | 1 | 2007 | 607 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2016 | 18048 | 0.060 |
Why?
|
Computational Biology | 1 | 2017 | 3543 | 0.060 |
Why?
|
Predictive Value of Tests | 4 | 2014 | 15455 | 0.060 |
Why?
|
Tenascin | 1 | 2024 | 61 | 0.060 |
Why?
|
Genotype | 5 | 2022 | 13042 | 0.060 |
Why?
|
Mycophenolic Acid | 1 | 2006 | 350 | 0.060 |
Why?
|
Dyslipidemias | 1 | 2012 | 873 | 0.060 |
Why?
|
Fasting | 1 | 2010 | 1610 | 0.060 |
Why?
|
Sex Factors | 4 | 2021 | 10654 | 0.060 |
Why?
|
Genome-Wide Association Study | 7 | 2017 | 12778 | 0.060 |
Why?
|
Holistic Health | 1 | 2024 | 48 | 0.060 |
Why?
|
Calcium | 2 | 2014 | 5794 | 0.060 |
Why?
|
Sleep Deprivation | 1 | 2010 | 848 | 0.050 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2010 | 1092 | 0.050 |
Why?
|
HLA Antigens | 1 | 2008 | 1337 | 0.050 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5538 | 0.050 |
Why?
|
Role | 1 | 2003 | 176 | 0.050 |
Why?
|
Transplantation, Homologous | 2 | 2008 | 4834 | 0.050 |
Why?
|
Double-Blind Method | 3 | 2023 | 12456 | 0.050 |
Why?
|
Case-Control Studies | 4 | 2023 | 22296 | 0.050 |
Why?
|
Angiopoietins | 1 | 2022 | 86 | 0.050 |
Why?
|
Cathepsin D | 1 | 2022 | 59 | 0.050 |
Why?
|
Amino Acids | 1 | 2008 | 1716 | 0.050 |
Why?
|
Angiopoietin-1 | 1 | 2022 | 122 | 0.050 |
Why?
|
Mortality | 3 | 2021 | 2917 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2012 | 2240 | 0.050 |
Why?
|
Energy Metabolism | 1 | 2013 | 2906 | 0.050 |
Why?
|
Echocardiography | 2 | 2015 | 5044 | 0.050 |
Why?
|
Receptor, TIE-2 | 1 | 2022 | 182 | 0.050 |
Why?
|
Educational Status | 1 | 2010 | 2518 | 0.050 |
Why?
|
Myocardium | 1 | 2015 | 4788 | 0.050 |
Why?
|
Vitamin K 1 | 1 | 2022 | 47 | 0.050 |
Why?
|
Logistic Models | 4 | 2021 | 13323 | 0.050 |
Why?
|
Primary Health Care | 1 | 2018 | 4748 | 0.050 |
Why?
|
Iohexol | 1 | 2022 | 205 | 0.050 |
Why?
|
Angiopoietin-2 | 1 | 2022 | 173 | 0.050 |
Why?
|
Kidney Tubules, Proximal | 1 | 2024 | 385 | 0.050 |
Why?
|
Treatment Refusal | 1 | 2005 | 432 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2012 | 2006 | 0.050 |
Why?
|
Hemodialysis, Home | 1 | 2021 | 21 | 0.050 |
Why?
|
Radial Artery | 1 | 2003 | 188 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2021 | 14784 | 0.050 |
Why?
|
Coronary Angiography | 2 | 2018 | 4537 | 0.050 |
Why?
|
Reoperation | 1 | 2012 | 4341 | 0.050 |
Why?
|
Hypertension, Renal | 1 | 2001 | 135 | 0.050 |
Why?
|
Survival Rate | 2 | 2013 | 12870 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2024 | 59686 | 0.050 |
Why?
|
Health Education | 1 | 2008 | 1057 | 0.050 |
Why?
|
Age Factors | 3 | 2017 | 18471 | 0.050 |
Why?
|
Naphthyridines | 1 | 2022 | 181 | 0.050 |
Why?
|
Intermittent Claudication | 1 | 2003 | 305 | 0.040 |
Why?
|
Glucose | 2 | 2022 | 4352 | 0.040 |
Why?
|
Adolescent | 6 | 2020 | 89184 | 0.040 |
Why?
|
Sodium, Dietary | 1 | 2024 | 426 | 0.040 |
Why?
|
Interferon Regulatory Factors | 1 | 2021 | 268 | 0.040 |
Why?
|
Hemostasis, Surgical | 1 | 2020 | 127 | 0.040 |
Why?
|
Treatment Outcome | 5 | 2018 | 65379 | 0.040 |
Why?
|
Life Style | 1 | 2011 | 3929 | 0.040 |
Why?
|
Blood Glucose | 2 | 2014 | 6430 | 0.040 |
Why?
|
Health Facilities | 1 | 2005 | 577 | 0.040 |
Why?
|
Gene Frequency | 2 | 2017 | 3617 | 0.040 |
Why?
|
Phenotype | 1 | 2018 | 16721 | 0.040 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2022 | 367 | 0.040 |
Why?
|
Vascular Patency | 1 | 2003 | 916 | 0.040 |
Why?
|
Teaching Rounds | 1 | 2024 | 282 | 0.040 |
Why?
|
Albumins | 1 | 2022 | 577 | 0.040 |
Why?
|
Cell Count | 1 | 2024 | 1833 | 0.040 |
Why?
|
Risk | 1 | 2011 | 9636 | 0.040 |
Why?
|
Protective Agents | 1 | 2020 | 150 | 0.040 |
Why?
|
Vitamin K | 1 | 2022 | 314 | 0.040 |
Why?
|
Patient Discharge | 1 | 2012 | 3476 | 0.040 |
Why?
|
Heart Diseases | 1 | 2012 | 2819 | 0.040 |
Why?
|
Hematuria | 1 | 2020 | 233 | 0.040 |
Why?
|
Nutrition Surveys | 2 | 2018 | 1736 | 0.040 |
Why?
|
Blood Proteins | 1 | 2024 | 1186 | 0.040 |
Why?
|
Medicare | 2 | 2021 | 6881 | 0.040 |
Why?
|
Glomerular Mesangium | 1 | 1999 | 98 | 0.040 |
Why?
|
Mendelian Randomization Analysis | 1 | 2024 | 1037 | 0.040 |
Why?
|
Linear Models | 3 | 2014 | 5878 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2010 | 4427 | 0.040 |
Why?
|
Parathyroid Hormone | 2 | 2017 | 1804 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2023 | 81801 | 0.040 |
Why?
|
Medicaid | 1 | 2012 | 2842 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2008 | 4250 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2012 | 5367 | 0.040 |
Why?
|
Sulfones | 1 | 2001 | 448 | 0.040 |
Why?
|
Models, Biological | 1 | 2014 | 9493 | 0.040 |
Why?
|
Public Health | 2 | 2021 | 2682 | 0.040 |
Why?
|
Education | 1 | 2020 | 535 | 0.040 |
Why?
|
Purines | 1 | 2001 | 615 | 0.040 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2024 | 1517 | 0.040 |
Why?
|
Chi-Square Distribution | 2 | 2015 | 3438 | 0.040 |
Why?
|
CpG Islands | 1 | 2021 | 1209 | 0.030 |
Why?
|
Anemia | 1 | 2006 | 1519 | 0.030 |
Why?
|
Mood Disorders | 1 | 2003 | 1129 | 0.030 |
Why?
|
Cathepsin C | 1 | 2015 | 4 | 0.030 |
Why?
|
Ultrasonography | 1 | 2009 | 6001 | 0.030 |
Why?
|
Cuba | 1 | 2015 | 48 | 0.030 |
Why?
|
Central America | 1 | 2015 | 69 | 0.030 |
Why?
|
Interpersonal Relations | 1 | 2003 | 1440 | 0.030 |
Why?
|
Dominican Republic | 1 | 2015 | 78 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3439 | 0.030 |
Why?
|
Urinalysis | 1 | 2018 | 369 | 0.030 |
Why?
|
South America | 1 | 2015 | 180 | 0.030 |
Why?
|
Cultural Competency | 1 | 2018 | 303 | 0.030 |
Why?
|
Up-Regulation | 2 | 2016 | 4142 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7453 | 0.030 |
Why?
|
Communication Barriers | 1 | 2018 | 419 | 0.030 |
Why?
|
Informed Consent | 1 | 2021 | 1010 | 0.030 |
Why?
|
Sulfotransferases | 1 | 2015 | 150 | 0.030 |
Why?
|
Hypercalcemia | 1 | 2017 | 423 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2023 | 2886 | 0.030 |
Why?
|
Mississippi | 1 | 2014 | 94 | 0.030 |
Why?
|
Puerto Rico | 1 | 2015 | 380 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7861 | 0.030 |
Why?
|
rab GTP-Binding Proteins | 1 | 2015 | 244 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2020 | 1309 | 0.030 |
Why?
|
Delayed Graft Function | 1 | 2014 | 53 | 0.030 |
Why?
|
Trust | 1 | 2018 | 532 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 1999 | 1627 | 0.030 |
Why?
|
Health Surveys | 1 | 2003 | 4056 | 0.030 |
Why?
|
Indians, North American | 1 | 2017 | 354 | 0.030 |
Why?
|
Mexico | 1 | 2015 | 767 | 0.030 |
Why?
|
Models, Economic | 1 | 2017 | 718 | 0.030 |
Why?
|
Genome, Human | 2 | 2017 | 4450 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2015 | 808 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36849 | 0.030 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2014 | 299 | 0.030 |
Why?
|
Research | 1 | 2020 | 1981 | 0.020 |
Why?
|
Diuretics | 1 | 2015 | 612 | 0.020 |
Why?
|
Animals | 5 | 2022 | 169337 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2017 | 1261 | 0.020 |
Why?
|
Hospital Bed Capacity | 1 | 2012 | 206 | 0.020 |
Why?
|
Emotions | 1 | 2003 | 2768 | 0.020 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2011 | 196 | 0.020 |
Why?
|
Health Status | 1 | 2024 | 4094 | 0.020 |
Why?
|
Serum Albumin | 1 | 2014 | 676 | 0.020 |
Why?
|
Life Expectancy | 1 | 2017 | 1249 | 0.020 |
Why?
|
Glucuronidase | 1 | 2011 | 205 | 0.020 |
Why?
|
Carotid Artery, Common | 1 | 2010 | 175 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2016 | 1752 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4076 | 0.020 |
Why?
|
Myocardial Contraction | 1 | 2015 | 1527 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2022 | 3587 | 0.020 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2011 | 595 | 0.020 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2015 | 1122 | 0.020 |
Why?
|
Electric Impedance | 1 | 2014 | 795 | 0.020 |
Why?
|
Glucocorticoids | 1 | 1999 | 2168 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 3064 | 0.020 |
Why?
|
Living Donors | 1 | 2014 | 651 | 0.020 |
Why?
|
Language | 1 | 2018 | 1558 | 0.020 |
Why?
|
Societies, Medical | 1 | 2021 | 3960 | 0.020 |
Why?
|
Myocardial Revascularization | 1 | 2012 | 796 | 0.020 |
Why?
|
Mental Health | 1 | 2003 | 3276 | 0.020 |
Why?
|
Hepatitis C | 1 | 1999 | 1593 | 0.020 |
Why?
|
Phosphates | 1 | 2012 | 765 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2014 | 1184 | 0.020 |
Why?
|
Regional Blood Flow | 1 | 2011 | 1502 | 0.020 |
Why?
|
Interleukin-1beta | 1 | 2014 | 1020 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2000 | 8562 | 0.020 |
Why?
|
Histocompatibility | 1 | 2008 | 322 | 0.020 |
Why?
|
Rats | 2 | 2015 | 23835 | 0.020 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2007 | 153 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8731 | 0.020 |
Why?
|
Pennsylvania | 1 | 2007 | 615 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2015 | 2819 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6541 | 0.020 |
Why?
|
Models, Cardiovascular | 1 | 2011 | 984 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2014 | 2003 | 0.020 |
Why?
|
Tibia | 1 | 2011 | 1075 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3267 | 0.020 |
Why?
|
Patient Selection | 1 | 2017 | 4266 | 0.020 |
Why?
|
Signal Transduction | 2 | 2022 | 23631 | 0.010 |
Why?
|
Cognition | 1 | 2022 | 7075 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3813 | 0.010 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2015 | 2144 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2013 | 20224 | 0.010 |
Why?
|
Poverty | 1 | 2015 | 2721 | 0.010 |
Why?
|
Computer Simulation | 1 | 2017 | 6277 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 1999 | 13020 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5512 | 0.010 |
Why?
|
Depression | 1 | 2003 | 8241 | 0.010 |
Why?
|
Drug Prescriptions | 1 | 2012 | 1673 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2011 | 6241 | 0.010 |
Why?
|
Myocytes, Cardiac | 1 | 2011 | 1685 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4357 | 0.010 |
Why?
|
Cadaver | 1 | 2007 | 1366 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 2007 | 1742 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2015 | 3941 | 0.010 |
Why?
|
Transcription Factors | 1 | 2021 | 12166 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2011 | 6510 | 0.010 |
Why?
|
Mice | 2 | 2022 | 82017 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2003 | 1337 | 0.010 |
Why?
|
Stroke Volume | 1 | 2012 | 5619 | 0.010 |
Why?
|
Heart Ventricles | 1 | 2010 | 3838 | 0.010 |
Why?
|
Bone Density | 1 | 2011 | 3559 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 14737 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 11918 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2005 | 4859 | 0.010 |
Why?
|
Chronic Disease | 1 | 2011 | 9379 | 0.010 |
Why?
|
Registries | 1 | 2012 | 8379 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2011 | 14481 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2013 | 15939 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2011 | 22355 | 0.010 |
Why?
|
DNA | 1 | 2007 | 7211 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2011 | 18362 | 0.010 |
Why?
|
Graft Rejection | 1 | 2005 | 4505 | 0.010 |
Why?
|